Literature DB >> 440817

Diphtheria-pertussis-tetanus vaccine: reactogenicity of commercial products.

R M Barkin, M E Pichichero.   

Abstract

Parents from four practices were surveyed to ascertain reactions of children to diphtheria-pertussis-tetanus (DPT) vaccine in the 48 hours after immunization. Vaccines were administered according to current recommendations. Responses were scored in three categories: temperature, behavioral changes, and local reactions. Questionnaires were returned by 1,232 (84.9%) patients. Only 7.0% reported no reaction, while 336 (27.3%) reported mild, 722 (58.6%) moderate, and 88 (7.1%) severe reactions. Over 50% experienced temperatures of at least 100 F, and 80% noted behavioral changes; 72.2% had local reactions. No encephalitis, seizures, or hospitalizations were reported. Reactogenicity was similar for the five immunizations of the recommended series and the two manufacturers evaluated. Reported reactions in the control group were significantly lower than in the study group. These reaction rates underline the need to reevaluate present DPT vaccines.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 440817

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  15 in total

1.  Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.

Authors:  P Boucher; H Sato; Y Sato; C Locht
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

2.  Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany.

Authors:  G Tormans; E Van Doorslaer; P van Damme; R Clara; H J Schmitt
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

3.  Immune response to the B oligomer of pertussis toxin.

Authors:  J L Arciniega; D L Burns; E Garcia-Ortigoza; C R Manclark
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

4.  Reactions to whooping cough vaccine.

Authors:  J B Stephenson
Journal:  Br Med J       Date:  1979-10-13

Review 5.  Pertussis vaccines--1993.

Authors:  H J Schmitt; S Wagner
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

6.  Whooping cough and pertussis vaccine.

Authors:  G T Stewart
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-23

Review 7.  Indications and contraindications for vaccines used in the Expanded Programme on Immunization.

Authors:  A M Galazka; B A Lauer; R H Henderson; J Keja
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

Review 8.  A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.

Authors:  S S Patel; A J Wagstaff
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

9.  Reactogenicity of fluid compared with adsorbed diphtheria-pertussis-tetanus vaccine.

Authors:  R G Mathias
Journal:  Can Med Assoc J       Date:  1984-06-15       Impact factor: 8.262

10.  Frequent symptoms after DTPP vaccinations.

Authors:  P L Verschoor; J T Wilschut; G A de Jonge; P J Kostense
Journal:  Arch Dis Child       Date:  1991-12       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.